Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial

NCT05233774 is registered in ClinicalTrials.gov with Longeveron Inc. as lead sponsor.

NCT NCT05233774
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05233774 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial
Lead sponsor
Longeveron Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 28, 2021
Completion date
September 29, 2023
Enrollment
50 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

mild alzheimer's disease